|Mr. Joseph S. Zakrzewski||Independent Investor & Independent Chairman of the Board||81.5k||N/A||1962|
|Dr. Markus F. Renschler M.D.||President, CEO & Director||718.62k||N/A||1961|
|Mr. Timothy Romberger||Independent Director||43.22k||N/A||1972|
|Dr. Kevin Mills Ph.D.||Co-Founder||N/A||N/A||N/A|
|Mr. David G. Gaiero||CFO & Treasurer||N/A||N/A||1978|
|Dr. Tom O'Shea Ph.D.||Senior Vice President of Clinical Pharmacology & Preclinical Development||N/A||N/A||N/A|
|Dr. Krisztina Nemenyi Ph.D.||Senior Vice President of Regulatory Affairs and Quality||N/A||N/A||N/A|
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.
Cyteir Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.